Advantages and disadvantages of direct oral anticoagulants in older patients

Submitted: 7 December 2017
Accepted: 4 February 2018
Published: 28 March 2018
Abstract Views: 2352
PDF: 717
HTML: 767
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Atrial fibrillation (AF) and venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, are conditions that increase with age. Anticoagulant therapy is strongly recommended both in patients with AF for the prevention of cardioembolic stroke, and for treatment of VTE and prevention of recurrent VTE. Until recently, vitamin K antagonists (VKAs) were the only oral drugs for long-term anticoagulation. In the past decade, four direct oral anticoagulants (DOACs) were approved: a direct thrombin inhibitor (dabigatran) and three factor Xa inhibitors (apixaban, rivaroxaban, edoxaban). Despite increasing evidence demonstrating the efficacy and safety of DOACs in older patients, there are still gray areas where the use of VKAs might be valuable.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Cherubini, A., Carrieri, B., & Marinelli, P. (2018). Advantages and disadvantages of direct oral anticoagulants in older patients. Geriatric Care, 4(1). https://doi.org/10.4081/gc.2018.7227

Similar Articles

You may also start an advanced similarity search for this article.